ZVRA at a glance
ZEVRA THERAPEUTICS, INC. (ZVRA, SEC CIK 1434647) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $106.5 million (up 350.9% from FY2024) and net income of $83.2 million. Diluted EPS was $1.35.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding ZEVRA THERAPEUTICS, INC. (ZVRA) shares worth $199.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by McFarlane Neil F. on October 12, 2026 of 20,000 shares at $11.25 per share.
- In the last 90 days, ZVRA insiders reported 0 open-market purchases ($0) and 1 open-market sale ($225K) on Form 4, a net sale of $225K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $106.5M
- +350.9% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$225K
- 13F holders
- 26 funds
- $199.9M · +0 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors since the March 31, 2026 Form 10-Q
- Carried-forward risks remain those disclosed in the December 31, 2025 Form 10-K
- Latest risk-factor update filed May 6, 2026 with the SEC
Management Discussion & Analysis
- Revenue $37.8M, up $11.7M YoY, driven by MIPLYFFA product sales increasing $11.6M
- Net income $19.2M vs $0.5M loss YoY, operating income $11.6M vs $4.1M
- MIPLYFFA strongest product, $11.6M YoY sales increase; OLPRUVA revenue $0.2M and sales efforts scaled back
- Cash, cash equivalents and investments $270.9M; nine-month operating cash flow $33.2M vs $(7.1)M
- EMA CHMP negative opinion on arimoclomol, re-examination requested; continued celiprolol Phase 3 development and commercial spending
AI summary of the ZVRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results and corporate updates announced for quarter ended September 30, 2026
- Investor conference call and audio webcast scheduled for November 3, 2026, at 4:30 p.m. ET
Item EX-99.1: Item EX-99.1
- Q3 revenue $37.8M, up $11.7M from Q3 2025, with MIPLYFFA contributing $34.0M
- Net income $19.2M, or $0.26 diluted EPS, versus a $0.5M loss, aided by $5.1M warrant and CVR liability gains
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results and corporate updates announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operating details
Item EX-99.1: Item EX-99.1
- Q2 net revenue $39.7M, up 53% YoY, with MIPLYFFA contributing $30.2M and global EAP reimbursements $9.0M
- Net income $8.8M, or $0.14 diluted EPS, versus $74.7M in Q2 2025 distorted by a $148.3M priority-review-voucher gain
Item 5.07: Submission of Matters to a Vote of Security Holders
- 78.37% of outstanding shares voted at the June 4, 2026 annual meeting
- Douglas W. Calder and Corey Watton elected as Class II directors through 2029
AI summaries of ZVRA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ZVRA
Don't miss the next ZVRA filing
- Alerts as it files. A push when ZVRA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ZVRA, by share count.
- Ask anything. An AI agent that reads every ZVRA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McFarlane Neil F. | Sell | Oct 12, 2026 | 20,000 | $11.25 |
| McFarlane Neil F. | M | Oct 10, 2026 | 50,000 | - |
| McFarlane Neil F. | M | Oct 10, 2026 | 50,000 | - |
| Thompson Rahsaan | Sell | Aug 14, 2026 | 42,666 | $11.13 |
| Watton Corey Michael | M | Aug 10, 2026 | 12,300 | - |
| Watton Corey Michael | M | Aug 10, 2026 | 12,300 | $4.97 |
| Watton Corey Michael | Sell | Aug 10, 2026 | 12,300 | $11.25 |
| Thompson Rahsaan | Sell | Jun 22, 2026 | 34,557 | $12.68 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $23.6M | $106.5M |
| Operating Income | - | -$87.0M | -$62.9M |
| Net Income | -$46.0M | -$105.5M | $83.2M |
| Op. Margin | - | -368.5% | -59.1% |
| Net Margin | - | -446.9% | 78.2% |
| Balance Sheet | |||
| Total Assets | $172.3M | $178.1M | $284.7M |
| Equity | - | $39.7M | $154.7M |
| ROE | - | -266.0% | 53.8% |
| Per Share | |||
| EPS | $-1.30 | $-2.28 | $1.35 |
| Cash Flow | |||
| Operating CF | - | -$69.7M | -$1.6M |
| CapEx | $296K | $0 | $835K |
Source: XBRL data in ZEVRA THERAPEUTICS, INC. (ZVRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ZVRA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $199.9M |
| Q2 2026 | 26 | $299.3M |
| Q1 2026 | 25 | $168.4M |
| Q4 2025 | 23 | $164.3M |
| Q3 2025 | 22 | $149.6M |
| Q2 2025 | 20 | $115.6M |
| Q1 2025 | 18 | $59.7M |
| Q4 2024 | 14 | $61.3M |
- Citadel Advisors LLC+436.8K (+3590%)
- Goldman Sachs Group+402.6K (+74%)
- State Street Corp+368.7K (+22%)
- Millennium Management+317.9K (+351%)
- Morgan Stanley+317.2K (+26%)
- Invesco Ltd−218.0K (-82%)
- AQR Capital Management−54.9K (-29%)
- Wells Fargo & Co−41.6K (-73%)
- D.E. Shaw & Co−39.3K (-3%)
- Franklin Resources−20.1K (-52%)
- Principal Financial Group+251.0K
- FMR LLC (Fidelity)−4.92M
Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ZVRA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| SC 13G | May 6, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Mar 26, 2026 | - | - | - |
| 4 | Mar 19, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | Analysis | - |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ZVRA SEC filings: frequently asked questions
Are ZVRA insiders buying or selling?
In the last 90 days, ZEVRA THERAPEUTICS, INC. (ZVRA) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $224,948 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ZVRA stock?
As of September 30, 2026, the largest ZEVRA THERAPEUTICS, INC. (ZVRA) holders among the 13F filers tracked by SignalX were BlackRock ($56.3 million), Vanguard Capital Management LLC ($28.8 million), State Street Corp ($22.5 million), Morgan Stanley ($16.7 million), D.E. Shaw & Co ($13.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ZVRA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $106.5 million (up 350.9% from FY2024) and net income of $83.2 million. Diluted EPS was $1.35. The figures come from the XBRL data in the 10-K.
What did ZVRA report in its latest 8-K?
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and corporate updates announced for quarter ended September 30, 2026.
What are the latest ZVRA SEC filings?
ZEVRA THERAPEUTICS, INC. (ZVRA) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 13, 2026.
What is ZVRA's SEC CIK number?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s SEC Central Index Key (CIK) is 1434647. EDGAR lists every ZVRA filing under that number.
Ask anything about ZVRA
The research agent reads ZVRA's filings, financials, insider trades and 13F holders, then answers with sources.